Table 3.

Number of drug–drug interactions (DDIs), and test for associations between parameters for the study population

(A) Number of drug–drug interactions (DDIs) for the study population
Number of DDIs	N (%)
None	5 (4.1%)
1–5	15 (12.2%)
6–10	29 (23.6%)
11–15	26 (21.1%)
16–20	15 (12.2%)
21–25	16 (13.0%)
≥26	17 (13.8%)

(B) Test for association between the number of prescribed medications and the estimated glomerular filtration rate (eGFR) for the study population
	Pre-ESRD Stage (eGFR ≥ 15ml/min)	ESRD Stage (eGFR 0–14ml/min)
1 – 5 Medications	13	5
6 – 10 Medications	18	25
11 – 15 Medications	5	46
≥16 Medications	1	10

(C) Test for association between the number of prescribed medications and the occurrence of DDIs among the study population
	DDIs present	DDIs absent
1–5 medications	14	4
≥6 medications	104	1

Notes: (A) Mean DDIs=15.69±11.00 interactions per patient. (B) Chi-X² =30.31, df =3, P-value =0.00000119 (significant), critical value=7.815, α =0.05. (C)Chi-X² =17.83, df =1, P-value = 0.00002421 (significant), critical value=3.841, α =0.05.

Abbreviation: ESRD, end stage renal disease.